Patient-Reported Outcomes and Hospitalization Data in Patients With HER2-Positive MBC Receiving Trastuzumab Deruxtecan vs Trastuzumab Emtansine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study
Ann. Oncol 2023 May 11;[EPub Ahead of Print], G Curigliano, K Dunton, M Rosenlund, M Janek, J Cathcart, Y Liu, PA Fasching, H IwataFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.